Compare NNAVW & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNAVW | DMAC |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | 103 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 347.5M |
| IPO Year | N/A | 2018 |
| Metric | NNAVW | DMAC |
|---|---|---|
| Price | $11.30 | $5.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 132.4K | ★ 137.1K |
| Earning Date | 03-12-2025 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,963,000.00 | $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 43.44 | N/A |
| 52 Week Low | $3.90 | $3.48 |
| 52 Week High | $13.41 | $10.42 |
| Indicator | NNAVW | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 66.34 | 36.43 |
| Support Level | $4.69 | $5.20 |
| Resistance Level | $13.41 | $6.40 |
| Average True Range (ATR) | 0.98 | 0.37 |
| MACD | 0.27 | -0.05 |
| Stochastic Oscillator | 94.64 | 13.51 |
NextNav Inc provides GPS service. The company NextNav TerraPoiNT system delivers resilient, next-generation, complementary positioning, navigation, and timing (PNT) solutions designed to overcome the limitations and vulnerabilities of existing space-based Global Navigation Satellite Systems (GNSS), including the Global Positioning System (GPS). The products of the company include NextNav Pinnacle: Accurate vertical location, NextNav 3D: 3D location visualization, NextNav TerraPoiNT: Resilient PNT for 3D and indoor geolocation, Next Generation Solution: Terrestrial 3D PNT powered by spectrum.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.